Profile data is unavailable for this security.
About the company
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
- Revenue in USD (TTM)18.36m
- Net income in USD-163.41m
- Incorporated2014
- Employees449.00
- LocationAdaptimmune Therapeutics PLC60 Jubilee Avenue, Milton ParkABINGDON OX14 4RXUnited KingdomGBR
- Phone+44 123 543 0000
- Websitehttps://www.adaptimmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tenaya Therapeutics Inc | 0.00 | -124.58m | 295.23m | 140.00 | -- | 1.87 | -- | -- | -1.65 | -1.65 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -57.91 | -- | -63.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 298.97m | 168.00 | -- | 0.6517 | -- | 7.37 | -3.36 | -3.36 | 0.5934 | 6.46 | 0.0775 | -- | 7.09 | 241,428.60 | -39.22 | -47.40 | -43.89 | -54.18 | -- | -- | -506.16 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Cartesian Therapeutics Inc | 25.91m | -254.87m | 303.05m | 38.00 | -- | -- | -- | 11.70 | -48.02 | -48.02 | 4.94 | -21.18 | 0.1077 | -- | 5.86 | 681,736.80 | -106.00 | -43.66 | -122.03 | -66.84 | -- | -- | -983.83 | -136.35 | -- | -0.5249 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Akebia Therapeutics Inc | 187.23m | -43.03m | 306.01m | 167.00 | -- | -- | -- | 1.63 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.34 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 83.44 | 69.13 | -22.98 | -82.25 | 1.31 | -4.82 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| MeiraGTx Holdings PLC | 11.38m | -74.11m | 306.74m | 402.00 | -- | 2.52 | -- | 26.95 | -1.27 | -1.27 | 0.1887 | 1.89 | 0.0381 | -- | 0.4821 | 27,159.90 | -24.81 | -26.40 | -31.62 | -32.66 | -- | -- | -651.19 | -420.70 | -- | -27.54 | 0.3729 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Adaptimmune Therapeutics PLC - ADR | 18.36m | -163.41m | 314.34m | 449.00 | -- | 12.89 | -- | 17.12 | -0.7285 | -0.7285 | 0.0834 | 0.0954 | 0.0672 | -- | 3.63 | 40,886.41 | -59.85 | -41.19 | -78.55 | -48.21 | -- | -- | -890.13 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Omeros Corp | 0.00 | -179.09m | 316.95m | 198.00 | -- | -- | -- | -- | -2.90 | -1.97 | 0.00 | -1.23 | 0.00 | -- | -- | 0.00 | -35.90 | -55.51 | -44.81 | -70.10 | -- | -- | -- | -- | -- | -5.39 | 1.19 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Enanta Pharmaceuticals Inc | 72.88m | -131.74m | 317.48m | 145.00 | -- | 1.91 | -- | 4.36 | -6.25 | -6.25 | 3.46 | 7.84 | 0.197 | -- | 5.70 | 502,627.60 | -35.60 | -14.56 | -40.33 | -15.62 | -- | -- | -180.75 | -54.96 | -- | -- | 0.0085 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Sutro Biopharma Inc | 154.07m | -114.96m | 318.18m | 300.00 | -- | 2.48 | -- | 2.07 | -1.89 | -1.89 | 2.53 | 1.57 | 0.4047 | -- | 7.48 | 510,149.00 | -30.20 | -25.48 | -36.94 | -29.75 | -- | -- | -74.62 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 322.66m | 275.00 | -- | 0.5908 | -- | 1.16 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Poseida Therapeutics Inc | 82.50m | -108.86m | 323.84m | 335.00 | -- | 3.82 | -- | 3.93 | -1.18 | -1.18 | 0.8907 | 0.8739 | 0.2864 | -- | 8.06 | 250,006.10 | -37.78 | -40.70 | -49.17 | -47.72 | -- | -- | -131.94 | -233.49 | -- | -12.88 | 0.4096 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -163.66m | 325.10m | 74.00 | -- | 0.6446 | -- | -- | -1.96 | -1.96 | 0.00 | 5.99 | 0.00 | -- | -- | 0.00 | -27.48 | -5.90 | -28.78 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| MacroGenics Inc | 43.36m | -23.24m | 333.84m | 339.00 | -- | 3.14 | -- | 7.70 | -0.3754 | -0.3754 | 0.6969 | 1.70 | 0.1465 | 5.13 | 2.00 | 127,896.80 | -7.85 | -37.76 | -9.48 | -45.53 | 84.28 | -- | -53.60 | -133.96 | 3.61 | -96.21 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| XOMA Royalty Corp | 5.81m | -45.09m | 336.12m | 13.00 | -- | 4.08 | -- | 57.84 | -3.92 | -3.92 | 0.5053 | 7.08 | 0.0329 | -- | 1,291.33 | 447,000.00 | -22.44 | -4.55 | -24.19 | -4.94 | -- | -- | -681.69 | -31.87 | -- | -24.55 | 0.5944 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
Data as of Jul 24 2024. Currency figures normalised to Adaptimmune Therapeutics PLC's reporting currency: US Dollar USD
48.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matrix Capital Management Co. LPas of 31 Mar 2024 | 38.97m | 15.25% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 27.40m | 10.72% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 15.87m | 6.21% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 10.79m | 4.22% |
| Long Focus Capital Management LLCas of 31 Mar 2024 | 10.68m | 4.18% |
| PFM Health Sciences LPas of 31 Mar 2024 | 10.42m | 4.08% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 4.66m | 1.82% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 2.43m | 0.95% |
| Tang Capital Management LLCas of 31 Mar 2024 | 1.44m | 0.57% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 1.39m | 0.55% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
